วีดีโอ

it was a great overview, thanks!

I wonder if there is a way to make a "universal" binding site... like a multitool used for screws, nuts, bolts all in one place.

Also their ability to deactivate killer T cells via PDL-1

Lol, I just found this after the final exams were over😣

Is plaque caused by macrophage-foam cells or LDL?

Hi, I’m a skilled video editor passionate about creating impactful content. I’d love the opportunity to bring my expertise to your projects! Is there any chance I could prove it to you?

👌👌👍

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, a compound designed to effectively turn back the biological clock and support longevity. Using advanced in vivo microfluidic technology, in collaboration with Nagi Biosciences SA, the study demonstrates significant age-reversal effects in aging model organisms treated with Telomir-1, effectively turning back the biological clock. These effects include an extended healthy lifespan, improved mobility, and a measurable reversal of age-related decline. Dr. Laurent Mouchiroud, Chief Scientific Officer at Nagi Bioscience commented: “At Nagi Bioscience, we are thrilled to contribute to this groundbreaking study through our innovative microfluidic technology, which allows precise and automated monitoring of aging and healthspan metrics in real-time. These results highlight Telomir-1’s remarkable potential to improve longevity and health, showcasing the power of cutting-edge tools in advancing age-reversal science.” By addressing the biological drivers of aging, Telomir-1 has the potential to profoundly impact patient care, offering new hope for managing and reversing age-related diseases while improving quality of life for countless individuals. Erez Aminov, Chairman and CEO of Telomir Pharmaceuticals, commented on the findings: “The results we are seeing with Telomir-1 mark an important step forward in our journey to potentially reverse aging in humans. This study confirms that Telomir-1 can reverse biological aging, extending life while preserving health. We are very excited about the potential applications of Telomir-1 as we progress toward human clinical trials.” Study Summary and Methodology The preclinical study, conducted in collaboration with Nagi Bioscience SA, utilized a sophisticated in vivo microfluidic-based assay to assess the effects of Telomir-1 on the nematode Caenorhabditis elegans, a well-established model for aging studies. The microfluidic platform allowed precise, automated tracking of lifespan, healthspan, and age-related mobility decline in real-time, enabling the research team to accurately measure the effects of Telomir-1 on these critical metrics. Two forms of Telomir-1 were administered in two concentrations, allowing the study to examine dose-dependent responses in treated subjects. The study found that Telomir-1 significantly enhanced lifespan and healthspan parameters in aged microorganism populations. Key findings included: Enhanced Mobility in Older Organisms: Subjects treated with Telomir-1 showed improved motility, particularly in later stages of life, compared to untreated controls. This enhanced movement in advanced age suggests a slowing of the aging process, as mobility is a key indicator of biological health. Reduced Biological Aging: The study demonstrated a measurable reversal of biological age markers in subjects treated with Telomir-1. This significant finding points to Telomir-1’s potential to slow down, and in certain aspects, reverse biological aging, making it a promising candidate for longevity treatments. Increased Lifespan: Telomir-1 was associated with a statistically significant increase in lifespan among treated populations. This further supports Telomir-1’s role in promoting longevity. Dr. Itzchak Angel, Chief Scientific Advisor at Telomir Pharmaceuticals, elaborated: “This study confirms that Telomir-1 not only extends life but also supports healthier aging, as evidenced by improvements in mobility and reduced age-related decline. These findings establish a promising foundation for Telomir-1 as a transformative treatment in age-reversal science.” Expanding Research and Future Applications Telomir is intensifying its focus on the potential use of Telomir-1 to treat progeria, a rare genetic disorder that causes accelerated aging in children. As part of these efforts, Telomir has engaged with the Progeria Foundation to investigate the effects of Telomir-1 on human progeria cell lines. This study will directly assess Telomir-1’s ability to counteract accelerated aging at the cellular level, offering critical insights into its therapeutic potential for progeria patients. In addition, Telomir has planned an in vivo study utilizing a progeria Caenorhabditis elegans model. This advanced microfluidic-based assay will evaluate Telomir-1’s impact on longevity, healthspan, and biological aging in an organismal context. Together, these two studies represent a comprehensive approach to understanding Telomir-1’s effects on progeria, targeting both cellular and whole-organism models of the disease. These initiatives build on Telomir-1’s demonstrated safety and efficacy in preclinical studies, which highlight its broad potential across various age-related conditions. Beyond progeria, Telomir is advancing research into chronic diseases such as diabetes, cancer, and inflammatory conditions. Ongoing discussions with a leading veterinary institution aim to establish a large-scale study on elderly dogs with osteoarthritis, further exploring Telomir-1’s potential to improve joint health and mobility. About Telomir Pharmaceuticals, Inc. Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in age-reversal science. The Company is focused on the development of Telomir-1, a novel small molecule designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. The Company’s goal is to explore the potential of Telomir-1 starting with ongoing research in animals and then in humans. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir’s goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.

Thanks !

Very useful

AI garbage. Reported.

Perfect ❤

My uncle's son faced severe gut dysbiosis, but after using IAFA Ayurveda's natural solutions, he experienced complete relief in just one month. The holistic approach truly made a difference in his health and well-being. We are incredibly grateful for IAFA Ayurveda and highly recommend their treatments to anyone in need!

Why?, what makes difference?

Best❤

What about insulin? Doesn’t it play a part?

Konopelski Via

❤❤❤❤❤❤

very nice thanks ❤

Very fantastic

👏🏻👏🏻👏🏻

Glycogen *

Thank you for the video! You state that the heart does'nt usually make new cells. What about ventricular hypertrophy as a result of training?

You should re-upload this excellent video at normal speed. I had to slow it to .85x.

This was so much better than so many other things TH-cam has shown me. It really makes me wonder about the algorithm stuff. I have diabetes and have read many books about it but this sirt of video helps the lay person to advance their understanding of the medical details.